139 related articles for article (PubMed ID: 29305921)
21. Pharmacokinetics of 40 kDa Polyethylene glycol (PEG) in mice, rats, cynomolgus monkeys and predicted pharmacokinetics in humans.
Sharda N; Khandelwal P; Zhang L; Caceres-Cortes J; Marathe P; Chimalakonda A
Eur J Pharm Sci; 2021 Oct; 165():105928. PubMed ID: 34265405
[TBL] [Abstract][Full Text] [Related]
22. A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations: Cannulation of the mesenteric and thoracic lymph ducts within the rat.
Boyd M; Risovic V; Jull P; Choo E; Wasan KM
J Pharmacol Toxicol Methods; 2004; 49(2):115-20. PubMed ID: 14990336
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
[TBL] [Abstract][Full Text] [Related]
24. Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers.
Barril G; Quiroga JA; Sanz P; Rodrìguez-Salvanés F; Selgas R; Carreño V
Aliment Pharmacol Ther; 2004 Jul; 20(1):37-44. PubMed ID: 15225169
[TBL] [Abstract][Full Text] [Related]
25. An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration.
Chan LJ; Feeney OM; Leong NJ; McLeod VM; Porter CJH; Williams CC; Kaminskas LM
Biomacromolecules; 2017 Sep; 18(9):2866-2875. PubMed ID: 28731677
[TBL] [Abstract][Full Text] [Related]
26. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients.
Lee S; Kim IH; Kim SH; Kim SW; Lee SO; Lee ST; Kim DG; Lee CS; Choi CS; Cho EY; Kim HC
Intervirology; 2010; 53(3):146-53. PubMed ID: 20068348
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats.
Kaminskas LM; McLeod VM; Ascher DB; Ryan GM; Jones S; Haynes JM; Trevaskis NL; Chan LJ; Sloan EK; Finnin BA; Williamson M; Velkov T; Williams ED; Kelly BD; Owen DJ; Porter CJ
Mol Pharm; 2015 Feb; 12(2):432-43. PubMed ID: 25485615
[TBL] [Abstract][Full Text] [Related]
29. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative.
Ramon J; Saez V; Baez R; Aldana R; Hardy E
Pharm Res; 2005 Aug; 22(8):1374-86. PubMed ID: 16078148
[TBL] [Abstract][Full Text] [Related]
30. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
[TBL] [Abstract][Full Text] [Related]
31. Catalytic enzyme activity concentration in thoracic duct, liver, and intestinal lymph of the dog, the rabbit, the rat and the mouse. Approach to a quantitative diagnostic enzymology, II. Communication.
Lindena J; Küpper W; Trautschold I
J Clin Chem Clin Biochem; 1986 Jan; 24(1):19-33. PubMed ID: 3701268
[TBL] [Abstract][Full Text] [Related]
32. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
[TBL] [Abstract][Full Text] [Related]
33. Quantification of a pegylated interferon-alpha2a product by a customised and validated reverse phase-high performance liquid chromatography method.
El Ghazaly M; Meager A; Zikry H; Ebaed M; Shaker S; Mueller F; Rohde J
J Pharm Biomed Anal; 2013 Oct; 84():48-52. PubMed ID: 23797040
[TBL] [Abstract][Full Text] [Related]
34. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
35. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
[TBL] [Abstract][Full Text] [Related]
36. The impact of lymphatic transport on the systemic disposition of lipophilic drugs.
Caliph SM; Cao E; Bulitta JB; Hu L; Han S; Porter CJ; Trevaskis NL
J Pharm Sci; 2013 Jul; 102(7):2395-408. PubMed ID: 23696002
[TBL] [Abstract][Full Text] [Related]
37. Intra-articular Injection of a B Cell Depletion Antibody Enhances Local Exposure to the Joint-Draining Lymph Node in Mice with Collagen-Induced Arthritis.
Lam AD; Styles IK; Senyschyn D; Cao E; Anshabo A; Abdallah M; Mikrani R; Nowell CJ; Porter CJH; Feeney OM; Trevaskis NL
Mol Pharm; 2023 Apr; 20(4):2053-2066. PubMed ID: 36945772
[TBL] [Abstract][Full Text] [Related]
38. Development of next generation of therapeutic IFN-α2b via genetic code expansion.
Zhang B; Xu H; Chen J; Zheng Y; Wu Y; Si L; Wu L; Zhang C; Xia G; Zhang L; Zhou D
Acta Biomater; 2015 Jun; 19():100-11. PubMed ID: 25769229
[TBL] [Abstract][Full Text] [Related]
39. Allergic sensitization to pegylated interferon-α results in drug eruptions.
Meller S; Gerber PA; Kislat A; Hevezi P; Göbel T; Wiesner U; Kellermann S; Bünemann E; Zlotnik A; Häussinger D; Erhardt A; Homey B
Allergy; 2015 Jul; 70(7):775-83. PubMed ID: 25831972
[TBL] [Abstract][Full Text] [Related]
40. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
De Leede LG; Humphries JE; Bechet AC; Van Hoogdalem EJ; Verrijk R; Spencer DG
J Interferon Cytokine Res; 2008 Feb; 28(2):113-22. PubMed ID: 18279106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
